MedTrace Logo

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

NCT07693426 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-07-30

No results posted yet for this study

Summary

This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose administration in Chinese adolescent participants with obesity.

Conditions

  • Adolescence Obesity

Interventions

DRUG

Efsubaglutide Alfa 5 mg QW

Efsubaglutide Alfa Injection Subcutaneous injection

DRUG

Efsubaglutide Alfa 10 mg QW

Efsubaglutide Alfa Injection Subcutaneous injection

DRUG

Efsubaglutide Alfa 20 mg QW

Efsubaglutide Alfa Injection Subcutaneous injection

DRUG

Efsubaglutide Alfa placebo

Efsubaglutide Alfa placebo Injection Subcutaneous injection

Sponsors & Collaborators

  • Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-16
Primary Completion
2027-04-30
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07693426 on ClinicalTrials.gov